The activation of AT1R, associated with vasoconstriction, sodium reabsorption, and growth promotion, leads to inflammation and the production of reactive oxygen species (ROS).[4,5] Therefore, blocking Ang II with an AT1 antagonist has become one of the best clinical options in the treatment of renal disease. Here, AGTR1 is linked to kidney disorder.